Clinical Progress Fails to Lift Cybin's Stock as Regulatory Revisions Weigh

Cybin's HLP004 achieved high response & remission rates in a Phase 2 anxiety trial with durable effects, but share price dropped as investors focused on corrected regulatory filings.

Despite announcing positive mid-stage clinical trial results for its anxiety treatment candidate, Cybin Inc. saw its share price decline. The market's reaction highlights how administrative corrections and broader sentiment can temporarily overshadow promising medical data.

Phase 2 Trial Demonstrates Efficacy in Anxiety Disorder

Cybin released data from a Phase 2 study evaluating HLP004, an investigational therapy for adults with moderate to severe anxiety symptoms who have not responded adequately to existing standard treatments. The randomized trial involved 36 participants and focused on intramuscular administration of the drug.

A dose of 20 milligrams yielded particularly strong outcomes. After a six-week period, the average reduction on the Hamilton Anxiety Scale was 10.4 points within this cohort. In the 20mg group, 59 percent of patients were classified as responders, with 32 percent achieving full remission. Even the lower 2mg dose produced clinically relevant effects, demonstrating response and remission rates of 30 percent each.

Durable Results and Favorable Safety Profile

Follow-up observations over six months indicated the treatment effects were sustained. Across the entire study population, 67 percent of participants were considered responders at the six-month mark, and 39 percent remained in remission.

The safety data for HLP004 was encouraging. No serious adverse events related to the drug candidate were reported. The acute effects lasted approximately 90 minutes, and most patients were clinically cleared for discharge about three hours after administration.

Administrative Revisions Dampen Market Sentiment

Coinciding with the clinical update, Cybin disclosed it had corrected formal errors in prior regulatory submissions. The company clarified references to registration documents and formally integrated financial reports for the quarter ending December 31, 2025, along with certain press releases from February 2026, into its current filings.

The confluence of these administrative steps with the clinical news appeared to unsettle investors. The stock extended its losses following the announcements, with technical indicators pointing to continued downward pressure post-data release. For now, the market's focus has shifted from the pipeline's medical advancements to a combination of profit-taking and these regulatory clarifications.